Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics

29.10.25 14:15 Uhr

Werte in diesem Artikel
Aktien

56,23 EUR 0,19 EUR 0,34%

Indizes

25.692,1 PKT 110,4 PKT 0,43%

23.578,1 PKT 73,0 PKT 0,31%

6.870,4 PKT 13,3 PKT 0,19%

The upcoming report from DexCom (DXCM) is expected to reveal quarterly earnings of $0.57 per share, indicating an increase of 26.7% compared to the year-ago period. Analysts forecast revenues of $1.18 billion, representing an increase of 18.4% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts.Analysts' assessment points toward 'Revenue- Hardware' reaching $39.65 million. The estimate indicates a year-over-year change of -6.5%.The average prediction of analysts places 'Revenue- Sensor and other' at $1.14 billion. The estimate points to a change of +19.6% from the year-ago quarter.It is projected by analysts that the 'Revenue- United States' will reach $843.25 million. The estimate suggests a change of +20.1% year over year.According to the collective judgment of analysts, 'Revenue- International' should come in at $332.15 million. The estimate points to a change of +13.6% from the year-ago quarter. View all Key Company Metrics for DexCom here>>> Over the past month, shares of DexCom have returned +2.9% versus the Zacks S&P 500 composite's +3.8% change. Currently, DXCM carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: DexCom und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf DexCom

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DexCom

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DexCom Inc.

Wer­bung

Analysen zu DexCom Inc.

DatumRatingAnalyst
02.08.2018DexCom BuyCanaccord Adams
03.05.2018DexCom BuyCanaccord Adams
23.03.2018DexCom OutperformRobert W. Baird & Co. Incorporated
28.09.2017DexCom OutperformWedbush Morgan Securities Inc.
15.09.2017DexCom Equal WeightBarclays Capital
DatumRatingAnalyst
02.08.2018DexCom BuyCanaccord Adams
03.05.2018DexCom BuyCanaccord Adams
23.03.2018DexCom OutperformRobert W. Baird & Co. Incorporated
28.09.2017DexCom OutperformWedbush Morgan Securities Inc.
03.05.2017DexCom BuyCanaccord Adams
DatumRatingAnalyst
15.09.2017DexCom Equal WeightBarclays Capital
30.04.2015DexCom PerformOppenheimer & Co. Inc.
27.01.2015DexCom PerformOppenheimer & Co. Inc.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DexCom Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen